Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
6.–10. rezultāts no 74.
23. lappuse
... terms apply to this section : ( 1 ) FDA means the Food and Drug Adminis- tration . ( 2 ) Adverse drug experience means any ad- verse event associated with the use of a drug in humans , whether or not considered drug related , including ...
... terms apply to this section : ( 1 ) FDA means the Food and Drug Adminis- tration . ( 2 ) Adverse drug experience means any ad- verse event associated with the use of a drug in humans , whether or not considered drug related , including ...
27. lappuse
... term " digi- talis " is used to designate the whole group . Typically , the glycosides are composed of three portions : a steroid nucleus , a lactone ring , and a sugar ( hence " glycosides " ) . ( This section should include a chemical ...
... term " digi- talis " is used to designate the whole group . Typically , the glycosides are composed of three portions : a steroid nucleus , a lactone ring , and a sugar ( hence " glycosides " ) . ( This section should include a chemical ...
29. lappuse
... terms of total amount accumulated . In previously undigitalized patients , a sin- gle loading dose of 0.5-0.75 milligram orally usually produces a detectable effect in 1-2 hours that becomes maximal in 6-8 hours . Additional doses of ...
... terms of total amount accumulated . In previously undigitalized patients , a sin- gle loading dose of 0.5-0.75 milligram orally usually produces a detectable effect in 1-2 hours that becomes maximal in 6-8 hours . Additional doses of ...
30. lappuse
... term use of digoxin is indicated in al- most all infants who have been digitalized for acute congestive heart failure unless the cause is transient . Many favor maintaining digoxin until at least 2 years of age in all in- fants with ...
... term use of digoxin is indicated in al- most all infants who have been digitalized for acute congestive heart failure unless the cause is transient . Many favor maintaining digoxin until at least 2 years of age in all in- fants with ...
33. lappuse
... term care facilities will be considered to have been pro- vided in accordance with this section if provided to the patient before adminis- tration of the first oral contraceptive and every 30 days thereafter , as long as the therapy ...
... term care facilities will be considered to have been pro- vided in accordance with this section if provided to the patient before adminis- tration of the first oral contraceptive and every 30 days thereafter , as long as the therapy ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning